Forbion

At Forbion Capital Partners we invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development.

The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. We focus on companies that have innovative technologies and drug development programs with unique advantages over current treatments. Furthermore, we invest in medical device companies with a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to market approval.

Our involvement continues beyond the initial investment. We work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of our portfolio company's products and technologies.

The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Throughout this time the Forbion team made new investments and has successfully divested from a series of companies, including Biovex, Pathway, Impella, Alantos, Glycart, Acorda, Argenta, Fovea and Borean.

Current funds under management exceed EUR 450M, split between four active funds and comprising some 27 promising portfolio companies.

Part of the capital invested from Forbion Capital Partner’s funds is provided by the ERP-EIF facility and the LfA-EIF facility, which is managed by the European Investment Fund.

Forbion closely collaborates with BioGeneration Ventures, a Netherlands-based venture capital firm investing in Dutch start-up and early stage life sciences companies.

• 2013

  2013

  	Date		Description
  	05.16.2013		CircuLite® Receives Approval to Begin CE Mark Trial for SYNERGY® IC Circulatory Support System CircuLite®, Inc. today announced that it has received approval from the Federal Agency for Medicines and Health Products in Belgium to commence the CE Mark trial of the SYNERGY® IC Circulatory Support System, the first mechanical support system that does not require major surgery. The SYNERGY IC System is based on the surgical SYNERGY® Circulatory Support System – the world’s smallest commercially available circulatory support pump - which is designed to treat ambulatory chronic heart failure patients (INTERMACS ≥4).
  	05.13.2013		Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prost...   Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcom prostate biopsy. James McKiernan, M.D., professor of urology and the director of urologic oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York City presents the da today at 8 a.m. PDT.
  	05.08.2013		Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Respo... Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company’s improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response.
  	05.07.2013		bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenk...   bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Wendy Dixon, Ph.D., and David Schenkein, M.D., have joined the company’s board of directors.
  	04.29.2013		Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors.
  	04.24.2013		arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders  arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development.
  	04.23.2013		Curetis raises EUR 12.5 million in Series B round Curetis AG today announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners, which has taken a EUR 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM will join Curetis’ supervisory board.
  	04.19.2013		Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therap...   Pieris AG has achieved the second milestone for the first of two programs in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin.
  	04.18.2013		Forbion Capital Partners co-leads €15 Million Series A Financing for Allecra Therapeutics Forbion Capital Partners, the Dutch life sciences venture capital firm, today announced that it has co-led the €15 million Series A financing round for Allecra Therapeutics GmbH, together with Edmond de Rothschild Investment Partners. EMBL Ventures was also part of the syndicate.
  	04.17.2013		Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted ... Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to discover and develop novel medicines using Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform.

• 2013

  	Date		Description
  	04.16.2013		Exosome Diagnostics Presents Data at the International Society for Extracellular Vesicles 2013 Annua... Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and microvesicle research.
  	04.10.2013		Pieris and Sanofi Broaden Existing Collaboration   Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin program. Under the existing framework of the 2010 agreement, the new program will entitle Pieris to an upfront payment from Sanofi and committed research funding as well as payments for the achievement of research, preclinical, regulatory and commercial milestones. Specific financial terms were not disclosed.
  	04.09.2013		Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Tri... Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.  The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by Johan Skog, Ph.D., the newly appointed chief scientific officer of Exosome Diagnostics.
  	03.25.2013		arGEN-X announces preclinical development of ARGX-112 for dermatology   arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.
  	03.21.2013		bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncolo...   bluebird bio, a privately-held biotechnology company focused on gene therapy, today announced the formation of a broad, global strategic collaboration with Celgene Corporation to discover, develop and commercialize novel disease-altering gene therapies in oncology. The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.
  	03.14.2013		Argos Therapeutics Welcomes Jean Lamarre to Board of Directors   Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the appointment of Jean Lamarre, president of Lamarre Consultants, to its Board of Directors.
  	03.06.2013		Curetis AG Strengthens Commercial Team and Expands Distribution Network   Curetis AG today announced The appointment of Helmut Hilbert as Head of Business Development and the expansion of its distribution network into Belgium and Luxembourg by closing a distribution agreement with ELITech BNL (former Lucron Bioproducts), an ELITech Group company.
  	03.05.2013		CircuLite® Receives Conditional IDE Approval for SYNERGY® Circulatory Support System feasibility Tri... CircuLite®, Inc. today announced that it has received conditional approval from the United States Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) for its lead product, the SYNERGY® Circulatory Support System, a minimally-invasive device designed to reverse the symptoms of heart failure in ambulatory chronic heart failure patients.
  	02.28.2013		Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001   Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that is has raised a total of €14.2m ($18.6m ) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001(previously TA-8995) and to develop additional earlier-stage dyslipidemia assets.
  	02.21.2013		uniQure Named to MIT Technology Review’s 2013 50 Disruptive Companies List Recognizing World’s Most ...   uniQure has been identified in the field of biomedicine as one of 2013’s 50 Disruptive Companies, MIT Technology Review’s annual list of theworld’s most innovative technology companies. The honorees are nominated by MIT Technology Review’s editors, who look for companies that have demonstrated original and valuable technology over the last year,are bringing that technology to market at significant scale, and are clearly influencing their competitors.Spanning energy and materials, Internet and digital media, computing and communications, biomedicine, and transportation, the 50 companies on the list represent the disruptive innovations most likely to change our lives.

• 2013

  	Date		Description
  	02.15.2013		Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metasta... Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced updated results from its Phase 2 study of AGS-003, its most advanced product candidate for the treatment of metastatic renal cell carcinoma (mRCC). The results, presented in a poster session at the 2013 ASCO Genitourinary Cancers Symposium in Orlando, continue to show prolonged survival in patients with unfavorable risk mRCC, with one-third of patients still alive after nearly four years or longer.
  	01.29.2013		Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum   Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced today its Chief Operating Officer and Vice President of Manufacturing, Dr. Frederick Miesowicz, will present during two focus sessions at Phacilitate's 9th Annual Cell and Gene Therapy Forum on January 28 and 29 in Washington, D.C.
  	01.22.2013		uniQure Appoints Philip Astley-Sparke President US uniQure B.V., the leader in the field of human gene therapy, today announced the appointment of Philip Astley-Sparke, former President and CEO of BioVex, as President US to provide strategic leadership and help build uniQure’s clinical, regulatory, and commercial infrastructure in the US.
  	01.22.2013		Dezima Pharma in-licenses CETP Inhibitor Program Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the inlicensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.
  	01.15.2013		Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate. AGS-003 is an investigational, fully personalized, dendritic-cell based immunotherapy. The ADAPT study is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend overall survival versus standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma (mRCC).
  	01.08.2013		arGEN-X Expands its Therapeutic Anitbody Alliance with Shire  arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody products, is broadening its therapeutic antibody collaboration with Shire. Initiated in March 2012, the existing alliance is focused on arGEN-X using its SIMPLE Antibody™ discovery platform to create novel human antibody therapeutics addressing diverse rare and unmet diseases being pursued by Shire.
  	01.08.2013		arGEN-X Initiaties Phase Ib Study of ARGX-110 in Cancer  arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery.

• 2012

  2012

  	Date		Description
  	12.17.2012		Promedior Opens New Office and Laboratories in Lexington, Mass. Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Massachusetts.
  	12.11.2012		uniQure licenses RNA interference technology uniQure B.V., a leader in the field of human gene therapy, today announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. (ASX: BLT) giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington’s disease. In return, uniQure granted Benitec non-exclusive access to the Company’s AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.
  	12.11.2012		uniQure initiates Phase I in acute intermittent porphyria uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient. The study is conducted under the aegis of the AIPGENE consortium, a pan-European collaboration funded in part by the European Commission’s Seventh Framework Program with the aim to develop a gene therapy for the treatment of AIP, a rare and devastating disease caused by mutations in the porphobilinogen deaminase gene(PBGD). AIP can be life-threatening and the long-term effects include irreversible nerve damage, liver cancer and kidney failure. uniQure was granted orphan drug designation for the treatment of AIP in 2009 from the European Medicines Agency.
  	12.11.2012		uniQure Appoints Hans Christian Rohde Chief Commercial Officer uniQure B.V., a leader in the field of human gene therapy, today announced the appointment of Hans Christian Rohde as Chief Commercial Officer.
  	12.10.2012		arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform arGEN-X, a biopharmaceutical company focused on the discovery and development of highly differentiated human monoclonal antibody therapeutics has received its first Notice of Allowance from the United States Patent and Trademark Office (USPTO) in connection with a portfolio of patent filings related to its SIMPLE Antibody™ discovery platform.
  	12.04.2012		Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of Unyvero Cartridge Plastic... Curetis AG today announced a strategic supply chain partnership with German family business Horst Scholz GmbH + Co. KG for the production of high-quality plastics parts for its Unyvero Cartridge. Under the agreement, Curetis will invest more than € 2 million in multi-cavity tools for all Unyvero™ Cartridge plastics parts. Curetis has already ordered several multi-cavity tools from Scholz. The first tools will be delivered in early 2013.  Scholz has been chosen by Curetis due to its unrivalled experience and expertise in medical device-grade injection molding, its state-of-the-art facilities and equipment as well as its cleanroom manufacturing infrastructure.
  	11.29.2012		Pieris Presents Data and Reveals Targets for Anticalin Bispecific In a presentation yesterday at the 8th Annual European Antibody Congress in Geneva, Switzerland, Pieris AG presented for the first time data for its PRS-190 bispecific Anticalin program targeting the Th17 pathway. The data revealed the generation of a highly specific and potent bispecific antagonist targeting IL-17 and IL-23, two key members of the Th17 family of cytokines, involved in autoimmunity and hyperinflammation. The single-gene multispecific drug candidate, whose individual building blocks could surpass existing available therapies against their respective target, creates several benefits ranging from efficacy, convenience, accelerated development timelines, ease of manufacturing and cost.
  	11.19.2012		Study shows innovative ERT‐based solution has the potential to address unmet clinical needs across a... Oxyrane, today announced the publication in Nature Biotechnology, results of its landmark study in novel enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs). Oxyrane, in collaboration with VIB researchers from Ghent University and Vrije Universiteit Brussels, have developed a new technology that enables a more efficient approach to ERT production for LSD treatments, as well as the potential to significantly improve future treatments for debilitating and often life‐threatening LSDs such as Pompe disease, Fabry disease and Hunter’s syndrome.
  	11.19.2012		Forbion Announces Appointment of Two Leading Experts in Oncology and Metabolic Disease as Scientific... Forbion Capital Partners today announced the appointment of Dr Kapil Dhingra, formerly global leader in oncology at Roche, and Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the University of Amsterdam, as Scientific Advsors. They will be advising on oncology and metabolic disease investment opportunies respectively.
  	11.15.2012		Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of its RNA-Based Im... Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings that confirms the Company’s current methods of analyzing RNA are robust and optimal for the assessment of RNA quality needed to develop the Company’s novel immunotherapies.  The study, which was published in the November issue of the Journal of Pharmaceutical and Biomedical Analysis, the journal of the American Association of Pharmaceutical Scientists, compared traditional slab electrophoresis currently in use at Argos to a newer microfluidics-based platform for performing various RNA analyses.

• 2012

  	Date		Description
  	11.13.2012		Insmed Announces CLEAR-108 Phase 3 Clinical Study Has Completed Target Enrollment Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CLinical Evaluation of ARIKACE (CLEAR-108) phase 3 European and Canadian registrational study of ARIKACE® (liposomal amikacin for inhalation) for Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections has now enrolled over 300 patients. CLEAR-108 is a randomized, phase 3 trial comparing ARIKACE 560 mg, delivered once daily via an optimized, investigational eFlow® Nebulizer System (PARI Pharma GmbH), to TOBI® (1) (tobramycin solution for inhalation), which is a commercially available inhaled antibiotic that is delivered twice daily. The study is being conducted in over 300 patients in Europe and Canada.
  	11.07.2012		Insmed Appoints Andrew Drechsler as Chief Financial Officer Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler to the position of Chief Financial Officer. Mr. Drechsler will assume the role of Principal Financial and Accounting Officer as of November 8, 2012.
  	11.02.2012		Southeast BIO Recognizes Argos Therapeutics with the "2012 Southeast BIO Deal of the Year Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its ArcelisTM technology platform, was presented with the "2012 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO) 14th Annual Investor Forum on November 1, 2012 in Palm Beach, FL. B. Jefferson (Jeff) Clark, a member of Argos Therapeutics’ Board of Directors, accepted the award on the behalf of company.
  	11.02.2012		Forbion Portfolio Company uniQure receives Approval for Glybera® First Gene Therapy by European Comm... Forbion Capital Partners is pleased to announce that its investee company, uniQure received approval today from the European Commission (EC) for the gene therapy Glybera® (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis. Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world.
  	10.26.2012		Exosome Diagnostics Selects Promega Corp. for cGMP Clinical Sample Concentrator Kit Exosome Diagnostics today announced it has reached an agreement with Promega Corporation to be the exclusive supplier of its Urine Clinical Sample Concentrator Kit. Promega will manufacture the Clinical Sample Concentrator Kit under current good manufacturing practices (cGMP) in their Madison, Wisconsin manufacturing facility. The kit incorporates Exosome's proprietary method for concentration of urinary exosomes, a standardized approach for providing clinical laboratories access to high quality preparations suitable for molecular diagnostics. The kit will be used to process urine samples for clinical trials in genitourinary disorders, including prostate cancer.
  	10.25.2012		ARGEN-X appoints Dr. David L. Lacey to its Supervisory Board arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey. Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the human anti-RANKL mAb denosumab, which was approved in 2010 by the U.S. Food and Drug Administration (FDA) under the trade name Prolia to treat osteoporosis in postmenopausal women and as Xgeva for the prevention of skeletal-related events in metastatic bone tumors. He was most recently responsible for leading more than 1,200 scientists in Amgen's discovery research unit across a portfolio of discovery and preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience.
  	10.15.2012		Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Elizabeth G. Trehu, M.D., as Chief Medical Officer (CMO). As CMO, Dr. Trehu will oversee all clinical development and regulatory activities for the company, as Promedior rapidly advances its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal diseases. Dr. Trehu is a seasoned biopharmaceutical executive with experience moving early stage R&D programs successfully through clinical development and product commercialization. She will report directly to Promedior’s CEO Suzanne Bruhn, Ph.D., and will serve as a member of the company’s executive management team.
  	10.15.2012		Promedior Expands Series D Round of Financing Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that it has completed a $24.5 million Series D financing round, adding $3 million in a second closing of this financing round from new investor, Shire Strategic Investment Group. The first close of the financing was led by another new investor, Fibrotec Ventures, LLC, and the round includes participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.
  	10.10.2012		Eric Rose, M.D., named Chairman of the CircuLite Board of Directors CircuLite  today announced the appointment of Eric Rose, M.D., as Chairman of its Board of Directors. Dr. Rose is a recognized leader in academic medicine and surgery and an entrepreneur. His interests range from device development to drug discovery, biodefense, clinical evaluative research and health policy. He is Executive Vice President of Life Sciences at MacAndrews & Forbes and has been a Director of CircuLite since November 2011.
  	10.09.2012		Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therap... Pieris AG announced today the achievement of the first financial milestone in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568). The milestone recognizes the on-schedule selection, optimization and characterization of several Anticalin drug candidates, developed using Pieris’ proprietary next-generation scaffold technology, against a Daiichi Sankyo target. The financial details of the milestone payment have not been disclosed.

• 2012

  	Date		Description
  	10.09.2012		Curetis Completes Enrollment for its EU Trial Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal.
  	10.04.2012		RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a... Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the achievement of certain clinical, regulatory and commercialization milestones and royalties based on worldwide net sales of therapeutic products.
  	09.27.2012		Amakem Initiates Phase 2a Proof of Concept Study with the Rho Kinase (ROCK) Inhibitor AMA0076 in Pat... Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension. The start of the study follows Amakem’s receipt of Investigational New Drug Application (IND) approval from the United States Food and Drug Administration (FDA). AMA0076 is a highly potent ROCK inhibitor and is based on Amakem’s ‘Localized Drug Action’ platform, which generates novel kinase inhibitors that minimize the risk of systemic as well as local side effects such as hyperemia.
  	09.26.2012		Teijin Pharma and Pulmagen Therapeutics Sign Exclusive Agreement Tokyo-based Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Pulmagen Therapeutics (Asthma) Limited, a UK-based drug development company, announce today an exclusive licensing agreement granting Teijin Pharma the rights to develop, manufacture and market ADC3680, a bronchial asthma therapeutic discovered by Pulmagen Therapeutics, in Japan.
  	09.20.2012		21st Century Health and Business highlighted novoGI novoGI Inc. today reported that 21st Century Health and Business, the health and medical related business television program, that showcases insights from cutting edge corporations around the world and innovative business strategies, highlighted novoGI and its compression anastomosis solution and its revolutionary approach to GI disease management.
  	09.19.2012		Curetis AG to Present Its UnyveroTM Solution at DGHM Conference Curetis AG today announced the presentation of its UnyveroTM Solution for the rapid molecular diagnosis of infectious diseases and the UnyveroTM P50 Pneumonia Cartridge during the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM) in Hamburg.
  	09.11.2012		Insmed Appoints Will Lewis as President and Chief Executive Officer Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced the appointment of Will Lewis as President and Chief Executive Officer, effective immediately. Mr. Lewis has also been appointed to the Company's Board of Directors. He succeeds Tim Whitten, who has resigned as President and Chief Executive Officer and as a member of the Company's Board of Directors. In addition, Donald J. Hayden, Jr., who was appointed Executive Chairman in May 2012, will return to his role as Chairman, effective immediately.
  	09.10.2012		Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO of BioVex, has joined the investment team as a venture partner based in Boston, USA. He will work with selected Forbion’s portfolio companies as a board member and/or advisor to help management to execute on their business plans.
  	09.05.2012		Forbion Portfolio Company Circulite® Receives CE Marking Approval For SYNERGY® Circulatory Support S... Forbion portfolio company CircuLite®, Inc. today announced that it has received CE Marking approval for the SYNERGY® Circulatory Support System, a micro-pump designed to halt the progression of heart failure.
  	07.25.2012		bluebird bio Secures $60 Million in Oversubscribed Financing Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple Clinical Programs in Severe Genetic Disorders, Including a Global ALD Phase 2/3 Study

• 2012

  	Date		Description
  	07.20.2012		Forbion portfolio company, uniQure receives positive opinion for Glybera® in Europe from CHMP
  	07.18.2012		Curetis AG Signs Distribution Deal in Middle East with ATC
  	07.05.2012		Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial
  	07.05.2012		uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson?s Disease
  	06.14.2012		novoGI? Announces Purchase of IP and Collaboration with Leading Gastroenterologist Dr. Christopher ...
  	06.13.2012		Cytheris appoints Damian Marron as chief executive officer
  	06.08.2012		Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients with Lupus at 2012 EULAR...
  	06.05.2012		Exosome Diagnostics Signs Agreement with Life Technologies to Use Real-Time PCR Platform for Exosom...
  	05.30.2012		INSMED PROVIDES CORPORATE UPDATE Company Sets Current ARIKACE? Development Priorities Insmed Projec...
  	05.23.2012		PneumRx, Inc. Acquires Key Broncus Assets

• 2012

  	Date		Description
  	05.23.2012		PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduct...
  	05.23.2012		Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility o...
  	05.16.2012		Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer
  	04.24.2012		arGEN-X Granted first US patent covering its unique NHance? technology
  	04.24.2012		Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patien...
  	04.04.2012		Pieris presents preclinical Data for PRS-110 at AACR Annual Meeting
  	03.28.2012		Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
  	03.20.2012		ARGEN-X APPOINTS ALAIN THIBAULT AS CHIEF MEDICAL OFFICER AND KOOS RASSER AS IP COUNSEL
  	03.20.2012		ARGEN-X LAUNCHES NHANCE? TECHNOLOGY TO GENERATE BETTER HUMAN ANTIBODY THERAPIES
  	03.20.2012		Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug

• 2012

  	Date		Description
  	03.12.2012		Promedior Receives U.S. Orphan Drug Designation for PRM‐151 for the Treatment of Idiopathic Pulmona...
  	03.12.2012		Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeli...
  	02.29.2012		ARGEN-X ENTERS INTO A THERAPEUTIC ANTIBODY ALLIANCE WITH SHIRE
  	02.17.2012		Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV
  	02.17.2012		Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics
  	02.09.2012		CELLNOVO LAUNCHES WORLD?S FIRST MOBILE-CONNECTED DIABETES MANAGEMENT SYSTEM WITH LARGEST EVER USABI...
  	02.09.2012		ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENT
  	02.08.2012		Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exo...
  	02.07.2012		Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program
  	02.06.2012		Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study o...

• 2012

  	Date		Description
  	02.01.2012		Argos Therapeutic Arcelis? Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically ...
  	02.01.2012		EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German F...
  	01.09.2012		AM-Pharma Announces Appointment of Russell Greig as Chairman

• 2011

  2011

  	Date		Description
  	12.19.2011		arGEN-X is awarded ?1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody? Platform for Addr...
  	12.13.2011		Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin? Program at ASH Annual M...
  	12.08.2011		Forbion Announces Closing of Second FCF 1 Co-Investment Fund
  	12.02.2011		Cellnovo's Mobile Health Approach to Diabetes Care
  	12.01.2011		Forbion portfolio company CircuLite, Inc raises $30m in Series D round
  	12.01.2011		FORBION PORTFOLIO COMPANY ARGEN-X RAISES EUR 27.5 MILLION (USD 37 MILLION) IN OVERSUBSCRIBED SERIES...
  	11.17.2011		Oxyrane Raises $26.5m in Series D Financing
  	11.15.2011		Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-E...
  	10.26.2011		Forbion Capital Partners leads € 9.6 Million Expansion Financing of Curetis AG
  	10.19.2011		Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin Pipeline De...

• 2011

  	Date		Description
  	10.18.2011		Forbion Capital Partners and Sofinnova participate in the € 7 million Series A Financing of Hookipa ...
  	10.14.2011		The Prostate Cancer Foundation and Exosome Diagnostics Collaborate to Accelerate Clinical Validatio...
  	10.05.2011		Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expa...
  	10.05.2011		Cardoz announces the successful completion of enrollment in the AORTA trial investigating CRD007 in...
  	10.04.2011		Cellnovo Receives 2011 European Technology Innovation Award in Diabetes Care
  	10.04.2011		Argos Therapeutics? Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicin...
  	09.13.2011		AM-Pharma Raises €29.2m in Series D Financing
  	09.06.2011		Forbion announces acquisition of Pathway Medical Technologies by Bayer Healthcare
  	09.06.2011		Forbion Capital Partners leads €18 Million Financing of Amakem NV
  	07.27.2011		ARGEN-X ANNOUNCES NON-EXCLUSIVE LICENSE WITH BIOWA FOR POTELLIGENT? TECHNOLOGY

• 2011

  	Date		Description
  	07.21.2011		Forbion Capital Partners leads CAD$7 Million Series A financing of gIcare Pharma, Inc.
  	07.11.2011		Insmed's ARIKACE? Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosi...
  	06.29.2011		Argenta signs integrated services agreement with Pulmagen Therapeutics
  	06.29.2011		Amsterdam Molecular Therapeutics? Glybera? Significantly Reduces the Risk of Pancreatitis in LPLD P...
  	06.27.2011		Amsterdam Molecular Therapeutics Receives Opinion on Glybera? Marketing Authorisation Application
  	06.08.2011		Cardoz announces the start of the international phase II dose-finding AORTA trial investigating a n...
  	06.06.2011		Argos Therapeutics? Arcelis? Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combi...
  	05.24.2011		Exosome Diagnostics Announces Expansion of Scientific Advisory Board
  	05.23.2011		Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin? PRS-080 Hepcidin Antagoni...
  	05.20.2011		Promedior Presents Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at American...

• 2011

  	Date		Description
  	05.12.2011		Santaris Pharma A/S advances a second drug from its cardiometabolic program, SPC4955, inhibiting ap...
  	05.10.2011		Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 20...
  	05.10.2011		BioGeneration Announces Closing of BioGeneration Ventures II
  	05.04.2011		Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduce...
  	04.20.2011		Promedior Announces Presentation of Data at ARVO Demonstrating that PRM-151 (rhPTX-2) Suppresses Ch...
  	04.20.2011		bluebird bio Secures Additional $30 Million in Financing
  	04.12.2011		Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin? Therapeutics
  	03.10.2011		Provesica Starts Phase 2 Study in Overactive Bladder
  	02.22.2011		Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri...
  	02.22.2011		IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology

• 2011

  	Date		Description
  	02.22.2011		IL-7 Knocks the Socs Off Chronic Viral Infection
  	02.22.2011		Cytheris Announces Publication of Preclinical Study in Cell Showing That Interleukin-7 Engages Mult...
  	02.15.2011		Xention and Gr?nenthal enter Drug Discovery Collaboration in Ion Channel Research
  	02.10.2011		Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor...
  	02.10.2011		Promedior Initiates Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in Patients with Idiopath...
  	02.04.2011		Cellnovo to Secure ?30 Million in Series B Financing
  	02.03.2011		Key Genes Associated with Cancer Found in Circulating Blood Microvesicles
  	01.31.2011		AMT Receives ? 1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as part of EU Cons...
  	01.25.2011		Forbion announces Amgen agreement to acquire portfolio company Biovex for up to US$1 billion
  	01.14.2011		AMT to Supply cGMP Manufacturing to Consortium Led by Institut Pasteur for Clinical Development of ...

• 2011

  	Date		Description
  	01.10.2011		Takeda San Francisco and Pieris Sign Anticalin? Therapeutic Collaboration
  	01.10.2011		Forbion Capital Partners leads $33 Million Series C financing of PneumRx, Inc.
  	01.05.2011		arGEN-X signs discovery and development alliance with Lilly
  	01.04.2011		Santaris Pharma A/S announces expanded worldwide strategic alliance with Pfizer Inc. directed to de...
  	01.04.2011		Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Monoclonal Antibody-Ba...

• 2010

  2010

  	Date		Description
  	12.23.2010		?4m Financing into Provesica to Complete Phase 2 Trial for Overactive Bladder
  	12.16.2010		Xention Spins Out Overactive Bladder Business - Demerged OAB company to be called Provesica Xention...
  	12.02.2010		Forbion Capital Partners announces that INSMED INCORPORATED and TRANSAVE, INC. combine their busine...
  	12.01.2010		Argos Therapeutics Initiates Dosing of Patients in Phase 2b Clinical Trial of Arcelis? Personalized...
  	12.01.2010		Cytheris Announces Publication of Clinical Case Study Combining Recombinant Human Interleukin-7 (CY...
  	11.24.2010		AMT Submits Responses to Day 120 Questions to EMA as part of the review process for Glybera
  	11.23.2010		Xention Raises ?8 Million in Private Equity Placement
  	11.05.2010		Argos Therapeutics? ArcelisTM Immunotherapy for Renal Cell Carcinoma Demonstrates Encouraging Resul...
  	11.05.2010		Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo with Enhanced Novel MicroR...
  	10.27.2010		ARIKACE? DEMONSTRATES SUSTAINED BENEFIT IN MULTIPLE STUDIES AND OVER MULTIPLE CYCLES OF TREATMENT O...

• 2010

  	Date		Description
  	10.07.2010		Amsterdam Molecular Therapeutics Successfully Raised ?14.3 m Through an Equity Issue
  	09.28.2010		Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therap...
  	09.27.2010		arGEN-X AWARDED ?1.5 MILLION IWT GRANT TO ACCELERATE PRE-CLINICAL ANTIBODY DEVELOPMENT
  	09.24.2010		AMT receives orphan drug designation from the U.S. Food and Drug Administration Duchenne Muscular D...
  	09.20.2010		Cardoz Raises SEK 124 M ($ 17 M, ? 13 M) in Series A Financing to Develop Drug for Aortic Aneurysm
  	09.17.2010		NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio?s Phase 1/2 Beta-T...
  	09.15.2010		Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor...
  	09.15.2010		Promedior Announces Initiation of Phase 2a Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in...
  	09.10.2010		Genetix Pharmaceuticals Renamed bluebird bio: Announces Appointment of Nick Leschly as Chief Execut...
  	09.03.2010		Forbion Capital Partners raises €190m for new investments

• 2010

  	Date		Description
  	08.18.2010		AMT?s Marketing Authorisation Application for Glybera? Progressing On Schedule
  	08.05.2010		Argos Therapeutics? Arcelis? HIV Immunotherapy Demonstrates Significant Reduction in Viral Load and...
  	07.15.2010		ARGEN-X GRANTED BROAD PATENT COVERING ITS UNIQUE SIMPLE ANTIBODYT PLATFORM
  	06.15.2010		Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
  	06.07.2010		Pieris AG Appoints Chief Scientific Officer
  	06.07.2010		Cytheris Closes ?12 Million ($15 Million) Series D Financing
  	05.25.2010		Amsterdam Molecular Therapeutics Reports Promising Data from Cholesterol-Lowering Gene Therapy Stud...
  	05.17.2010		Forbion Capital Partners co-leads $20 Million Series A Financing of Exosome Diagnostics
  	05.10.2010		Forbion Capital Partners Leads € 10 M Series A Financing in Cardoz to Develop Drug for Aortic Aneury...
  	05.06.2010		Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program

• 2010

  	Date		Description
  	05.06.2010		Argos Therapeutics Presents Transplantation Data for Soluble CD83 Demonstrating its Ability to Indu...
  	03.19.2010		Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arceli...
  	03.19.2010		Argos Therapeutics Presents Positive Phase 2 Data of its ArcelisTM Personalized Immunotherapy Platf...
  	03.16.2010		Forbion Capital Partners Opens German Office and Expands Team Forbion Capital Partners Opens German Office and Expands Team.
  	03.16.2010		Forbion Capital Partners leads $12 Million Series C Financing of Promedior Inc.
  	03.15.2010		Genetix Pharmaceuticals secures $35M in Series B Funding
  	03.15.2010		arGEN-X SIMPLE ANTIBODY™ PLATFORM SET TO TRANSFORM THERAPEUTIC ANTIBODY DISCOVERY & DEVELOPMENT
  	03.12.2010		Amsterdam Molecular Therapeutics Amends Amgen GDNF Gene License Agreement
  	03.12.2010		AMT initiates Phase I/II Gene Therapy Clinical Trial for Hemophilia B
  	03.12.2010		Genetix Pharmaceuticals appoints Mitchell Finer, Ph.D. as Chief Scientific Officer

• 2010

  	Date		Description
  	02.03.2010		Galapagos acquires Argenta Discovery's service operations
  	01.25.2010		EMA starts formal review of Glybera? dossier
  	01.20.2010		AMT submits its lead product Glybera? Application for Marketing Authorisation Application to EMA
  	01.04.2010		Pieris appoints a new CEO

• 2009

  2009

  	Date		Description
  	12.16.2009		Amsterdam Molecular Therapeutics (AMT) successfully raises EUR 5 million via a Convertible Bond iss...
  	12.03.2009		arGEN-X concludes EUR 12.5 million Series A financing round
  	11.13.2009		PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain
  	11.11.2009		Genetix Pharmaceuticals Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD)
  	11.11.2009		AMT Successful in Preclinical Treatment of Duchenne Muscular Dystrophy
  	11.04.2009		BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEX GM-CSF IN THE JOURNAL OF CLIN...
  	11.03.2009		arGEN-X is awarded ?1.3 million grant for the development of its novel SIMPLE Antibody? Platform
  	10.29.2009		AMT Starts Development LPLChip(TM) with Progenika
  	10.27.2009		TRANSAVE COMPLETES SUCCESSFUL PHASE II CLINICAL PROGRAM FOR ARIKACE IN THE TREATMENT OF PSEUDOMONAS...
  	10.21.2009		Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis? HIV P...

• 2009

  	Date		Description
  	10.13.2009		AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
  	10.12.2009		Pieris reports preclinical development progress of its next generation VEGF antagonist
  	10.01.2009		Sanofi-aventis to acquire FOVEA Pharmaceuticals, a French biopharmaceutical ophthalmology company
  	09.24.2009		Joern Aldag appointed as AMT's CEO
  	09.16.2009		Cytheris Announces Interim Data From INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Depe...
  	09.15.2009		Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
  	09.15.2009		Transave announces positive phase II results for once-daily Arikace? in the treatment of non-cf bro...
  	09.10.2009		Forbion Capital Partners co-leads EUR 9.5 million financing of arGEN-X B.V.
  	08.14.2009		Forbion Capital Partners leads $18.5 million financing of NiTi Surgical Solutions
  	06.29.2009		Synergy?, Circulite's Micro-blood pump, shown to provide sustained improvements in cardiac function...

• 2009

  	Date		Description
  	06.09.2009		PanGenetics Receives Approval for Clinical Evaluation of Anti-NGF Antibody in Patients with Chronic...
  	05.20.2009		Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
  	05.18.2009		Argenta Discovery Announces Entry into Phase I for First Candidate from Collaboration with AstraZen...
  	05.14.2009		Argenta Discovery and Porsolt Join Forces to Provide Fully-integrated CNS and Pain Contract Drug Di...
  	05.13.2009		Cytheris Announces Publication of IL-7 Primate Study Showing Rapid and Massive T cell Homing to the...
  	05.07.2009		AMT Starts Preregistration Trial for Glybera
  	05.05.2009		Fovea Reports Positive Results with PrednisporinTM in Persistent Allergic Conjunctivitis
  	04.22.2009		TRANSAVE COMPLETES ENROLLMENT IN ARIKACETM PHASE II BRONCHIECTASIS STUDY
  	04.14.2009		BIOVEX COMMENCES ONCOVEX GM-CSF PIVOTAL TRIAL IN MELANOMA
  	04.01.2009		CIRCULITE DEMONSTRATES LONG-TERM IMPROVEMENTS AND HEMODYNAMIC BENEFITS WITH SYNERGY? PARTIAL CIRCUL...

• 2009

  	Date		Description
  	04.01.2009		CIRCULITE? COMPLETES INITIAL CLOSE ON $33 MILLION SERIES C FINANCING PLAN AND APPOINTS CHIEF MEDICA...
  	03.30.2009		BIOVEX RAISES $40 MILLION IN FIRST CLOSE OF SERIES F FINANCING
  	03.12.2009		Xention Enters Drug Discovery Agreement with Ono Pharmaceutical Co., Ltd.
  	03.05.2009		Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
  	02.10.2009		DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner o...
  	02.03.2009		Pieris reports development progress for Anticalin? PRS-050, a next generation VEGF antagonist
  	01.26.2009		AMT CEO Ronald Lorijn Steps Down - Sander van Deventer Interim CEO

• 2008

  2008

  	Date		Description
  	12.02.2008		Mitralign Initiates it's First European Study
  	11.24.2008		Argos Therapeutics Completes $35.2 Million Series C Financing
  	10.20.2008		AMT intents to incorporate additional data to its marketing Authorization Dossier for Glybera
  	09.18.2008		AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Pr...
  	09.16.2008		Pathway Medical Technologies Receives FDA Clearance for Jetstream Pathway PV Atherectomy System
  	06.25.2008		AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera?)
  	06.25.2008		AMT Announces Positive Interim Clincal Data on its Lead Product AMT-011
  	06.25.2008		Biovex reports positive phase II clinical trial results of Oncovex GM-CSF in metastatic melanoma at ...
  	05.26.2008		AMT?s Cooperative Research and Development Agreement with NIH to Boost Production Capacity
  	05.26.2008		AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

• 2008

  	Date		Description
  	04.24.2008		Pathway Medical Technologies, Inc. Secures $24.5 Million Financing
  	04.23.2008		Argos Therapeutics Secures $35.2 Million Series C Financing
  	04.02.2008		Forbion’s Portfolio Company Transave, Inc. Raises $35 Million Through Series D Convertible Preferred...
  	04.01.2008		Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis™ Platform in HIV at Keyston...
  	03.27.2008		Forbion’s Portfolio Company Pieris AG raises € 25 M (US$ 38M) in Series B financing round
  	03.18.2008		Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
  	03.07.2008		CircuLite announces initiation of European registration study for Synergy™ Circulatory Assist Device
  	03.05.2008		Forbion Capital Partners co-invests in 23M EURO series C financing of PanGenetics
  	02.28.2008		Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
  	02.21.2008		Circulite reports preliminary results of first-in-man pilot study for Synergy circulatory assist dev...

• 2008

  	Date		Description
  	02.13.2008		Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-7...
  	02.07.2008		Mitralign Successfully Completes First Human Case
  	01.30.2008		Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes for Personalized Immunotherapy T...
  	01.28.2008		Forbion Capital Partners co-leads $24m Series C Financing of Mitralign
  	01.28.2008		AMT’s Lead Product Poised to Address Major Liver Disease: European Patent Office Grants Patent for T...

• 2007

  2007

  	Date		Description
  	12.20.2007		Forbion Capital Partners expands investment team with Sr. Analyst and Venture Partner
  	12.18.2007		Santaris Pharma raises €20 million of new equity
  	12.13.2007		Forbion Capital Partners leads EUR30M Series B Financing in Fovea Pharmaceuticals S.A.
  	12.11.2007		BioVex closes second round of series E financing - 15 November 2007
  	12.11.2007		BioVex appoints Genzyme executive Jan van Heek as chairman of the Board of Directors - 25 October 20...
  	12.10.2007		Mitralign Announces the Closing of a $24M Series C Financing
  	12.03.2007		Cytheris Releases Promising Clinical Data on it's Interleukin-7 Immune Enhancer at the 2007 CROI Mee...
  	11.27.2007		Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong...
  	09.24.2007		FlowMedica Inc. Launches the Benephit® XT Infusion System. The Next-Generation System for Target...
  	08.30.2007		FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry - 2...

• 2007

  	Date		Description
  	08.23.2007		Pathway Medical Technologies Adds Joe Rafferty as VP, Sales,And Moves to Larger Facility to Accommod...
  	08.09.2007		AMGEN TO ACQUIRE ALASKA PHARMACEUTICALS
  	08.09.2007		Revolutionary Miniature Blood pump from Circulite successfully implanted in first chronic heart fail...
  	07.10.2007		Biovex Raises $22 Million in First Close of Series E Financing
  	07.10.2007		Bram Bout Joins Bioceros as CEO
  	06.21.2007		Amsterdam Molecular Therapeutics announces pricing of Initial Public Offering
  	06.21.2007		Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration ...
  	06.07.2007		Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext Amste...
  	06.05.2007		Forbion Announces Successful Exit from Alantos Pharmaceuticals
  	06.04.2007		AMT Receives Orphan Drug Designation from FDA for AMT 011 for the Treatment of Lipoprotein Lipase De...

• 2007

  	Date		Description
  	05.31.2007		AMT Presents Positive Results of Phase I/II Study with Lead Product at Annual Meeting of American So...
  	05.24.2007		AMT appoints Ferdinand Verdonck as Chairman of the Supervisory Board
  	05.24.2007		Amsterdam Molecular Therapeutics announces intention to launch an Initial Public Offering (IPO) on E...
  	05.09.2007		Pieris AG, a biopharmaceutical company developing Anticalins, a novel class of targeted human protei...
  	05.07.2007		Forbion Capital Partners adds top tier investors to its investor base
  	04.23.2007		CircuLite™ Closes an Additional $5M in Series B Private Placement Funding
  	04.02.2007		Argos Therapeutics Awarded U.S. Patent for CD83 Protein for Use in Immunological Disorders
  	04.02.2007		Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin® in preclinical studies
  	04.02.2007		ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
  	04.02.2007		CircuLite™ Closes $20M Series B Private Placement Funding

• 2007

  	Date		Description
  	03.12.2007		Argos Therapeutics Initiates Personalized Immunotherapy Clinical Trial in HIV Patients
  	03.12.2007		Amsterdam Molecular Therapeutics BV receives global rights to develop and commercialize AMT-020 for ...
  	03.12.2007		Forbion Partner Sander van Deventer receives award for development of new therapies for Crohn's dise...
  	03.12.2007		AM-Pharma announces the appointment of Bart Wuurman as CEO
  	03.12.2007		Pangenetics B.V. licenses therapeutic antibody from Schering Plough Corporation
  	03.12.2007		Jan van Heek joins PanGenetics' Supervisory Board
  	01.31.2007		B-Cell Chronic Lymphocytic Leukemia Clinical Trial Initiated with Argos Therapeutics' AGS-005 Person...
  	01.31.2007		Argenta Discovery and AstraZeneca sign a Research Collaboration and Licensing Agreement to Discover ...
  	01.26.2007		FDA approves Enzon IND for Santaris Pharma's Second New Cancer Drug

• 2006

  2006

  	Date		Description
  	12.13.2006		Analysis by AlgoNomics reveals that Anticalins® intrinsically have an immunogenicity level comparabl...
  	12.12.2006		Amsterdam Molecular Therapeutics BV (AMT) Acquires License to AAV Patents from Targeted Genetics Cor... Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction. Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.
  	11.17.2006		First closing of BioGeneration Ventures Fund
  	11.02.2006		Pathway Medical closes $25 million Series B funding raising
  	10.25.2006		Pieris confirms in vivo activity of potent VEGF-specific Anticalin
  	10.25.2006		Cytheris closes EUR 24.3M (USD 30.7M) Series B financing Funds to progress Phase II clinical studies...
  	10.24.2006		Alantos pharmaceuticals and servier form collaboration
  	10.12.2006		Claus Braestrup, CEO of Lundbeck, appointed to Santaris Pharma Board Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas ac libero vel erat tincidunt euismod. Etiam faucibus eleifend arcu, non consequat justo lobortis et. Sed egestas, enim et tempus tristique, augue lectus mattis mi, eu condimentum nibh purus quis felis. In pharetra leo aliquam massa porttitor nec blandit felis bibendum. Proin egestas sapien quis purus elementum ut egestas purus molestie. Etiam fermentum, dui nec vestibulum posuere, massa velit tincidunt nisi, nec ultricies erat libero quis enim. Maecenas rutrum, nibh in blandit volutpat, risus massa ullamcorper turpis, non semper metus diam sed augue. Aenean lorem lacus, vestibulum a faucibus a, elementum sit amet sem. Aliquam dolor leo, vehicula quis tincidunt ut, posuere sed neque. Maecenas nisl diam, hendrerit non venenatis vel, malesuada vitae turpis. Sed scelerisque pharetra consectetur. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Fusce a massa lorem, ut luctus lacus. Morbi a dolor erat, sit amet porta neque. Praesent consequat, lacus quis vulputate commodo, eros sapien fermentum massa, et luctus libero ante a quam. Nulla pulvinar dapibus tempus. Aliquam sed nisi dolor, at vulputate risus. In est arcu, suscipit non eleifend sed, venenatis eu est. Nullam justo nisi, bibendum eget pulvinar sed, ultrices scelerisque metus. Vivamus fermentum leo et risus aliquet nec pulvinar lorem convallis. Quisque rutrum, mi non accumsan mollis, lectus ante euismod elit, in pulvinar lectus orci eu sapien. Etiam auctor eleifend felis, id mattis tortor consectetur ac. Curabitur nec est velit, eget vehicula quam. Vestibulum eleifend condimentum congue. Aliquam dictum purus vel turpis porta pretium. In consequat, sapien et feugiat ultricies, mi augue egestas massa, tempor ullamcorper justo est non massa. Sed auctor enim at tellus viverra vitae consequat felis imperdiet. Nullam vitae vehicula magna. Etiam elementum diam id dolor tincidunt ac sagittis neque consectetur. Nullam in feugiat lectus. Aliquam sollicitudin tempus tristique. Nullam bibendum mauris vel magna fermentum adipiscing. Duis vestibulum turpis vel magna accumsan tempor. Aenean lorem ligula, ornare vel vehicula quis, placerat et nisi. Pellentesque urna nunc, aliquam ac adipiscing eu, mollis a tortor. Praesent pharetra libero pulvinar arcu luctus tristique. Pellentesque a pharetra est. Nullam bibendum, elit vel congue facilisis, lorem risus aliquam justo, non aliquet magna odio quis dui. Nullam convallis porta libero eu bibendum. Nulla eu tortor nec turpis mollis consectetur. Vivamus eget augue at lacus dictum consequat. Praesent in velit arcu, pellentesque tincidunt sem. Pellentesque in consequat lacus.